We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

COVID-19 Drug Study for Out-Patient Care

This study is closed to recruitment.

Phase 2/3 of RHB-107 (Upamostat), a Serine Protease Inhibitor or Placebo for Treatment of COVID-19 Disease

Upamostat, a Serine Protease Inhibitor or Placebo for Treatment of COVID-19 Disease
AGE: > 18 years old
GENDER: All
HEALTHY PARTICIPANTS: No
TYPE: Experimental Treatment Study
CONDITION: COVID-19, Coronavirus
COMPENSATION: Compensation and parking vouchers may be provided.

Purpose of the Study

The purpose of this study is to test the safety of the study drug RHB-107, also referred to as Upamostat, in two different doses to see if it can help people with early COVID-19. Participants in this study will receive either a high or low dosage of Upamostat and/or placebo and will take it by mouth once per day for 14 days.

 

Study ID